Measuring the economic benefit of treatment with atypical antipsychotics.
From receptor to outcome : the impact of atypical antipsychotics in schizophrenia. Satellite symposium. London, GBR, 1996/07/07.
Schizophrenia has a major impact on the quality of life of sufferers, and its broader impact on families and on society are well known, although less thoroughly documented.
The majority of sufferers require long-term treatment and support, and there are depressingly frequent media stories about violent incidents involving people with the illness.
Consequently the costs of schizophrenia, broadly defined, loom large, not just from the perspective of health care decision-makers and governments, but also from that of sufferers and their families, to many other people with only indirect experience of the disease.
Mots-clés Pascal : Schizophrénie, Chimiothérapie, Traitement, Neuroleptique, Atypique, Psychotrope, Analyse coût, Economie santé, Coût social, Analyse économique, Hospitalisation, Article synthèse, Santé mentale, Homme, Psychose
Mots-clés Pascal anglais : Schizophrenia, Chemotherapy, Treatment, Neuroleptic, Atypical, Psychotropic, Cost analysis, Health economy, Social cost, Economic analysis, Hospitalization, Review, Mental health, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0196052
Code Inist : 002B02B03. Création : 11/09/1998.